Partnership to focus on nutraceutical gum
April 27, 2011
by Jeff Gelski
VEJLE, DENMARK — Gumlink has acquired a 50% stake in Tab Labs, Inc., Langley, B.C., to create a partnership with a primary focus on patented nutraceutical chewing gum. Tab Labs has experience in adding sensitive active ingredients, such as probiotics, to chewing gum. Vejle-based Gumlink will contribute its nutraceutical chewing gum capabilities and its R.&D. facilities.
Chris Chilcott, chief technology officer for Gumlink, has joined the Tab Labs management team and will lead Tab Labs’ new nutraceutical innovation center. Dr. Chilcott was involved in the development of patented, oral probiotic strains Blis K12 and Blis M18 at Blis Technologies Ltd. in New Zealand.
“Gumlink brings to Tab Labs scale, infrastructure and resources that will allow us to take all aspects of our business to the highest levels,” said Tom Holtgen, chief executive officer of Tab Labs. “Our common vision and synergies are very complementary and will result in many new exciting innovations and discoveries. Tab Labs is now positioned to take ownership as North America’s leading nutraceutical chewing gum innovator and contract manufacturer.”
Soren Birn, c.e.o. of Gumlink, said, “This move makes perfect sense for us, as it will provide us with a nutraceutical manufacturing and distribution platform in North America and provide access to novel technologies that when combined with our own proprietary gum technologies will enable us to offer the most potent nutraceutical chewing gum assortment.”